Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NexImmune, Inc. (NEXI)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Pharmaceuticals
Address
9119 Gaither Road 20877
Gaithersburg, MD, US
Gaithersburg, MD, US
CEO
Craig R. Jalbert
Website
neximmune.com
IPO
2021-02-12
ISIN US65344D2080
Description
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
438
Beta
3.44
Float Shares
1.18M
Free Float %
84.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -50.00% | +0.00% | +9,900.00% | +0.00% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Low
2.00
+1,999,900.0%
Consensus
3.33
+3,329,900.0%
Median
3.00
+2,999,900.0%
High
5.00
+4,999,900.0%
DCF (Unlevered)
1.75
+1,754,796.0%
DCF (Levered)
2.99
+2,985,834.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 3 |
3.33
+3,329,900.0%
|
Quality scores
Altman Z-Score
-64.97
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%-105.8% Q2'24: +76.7% (vs Q2'23)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%— Q2'24: +726.2% (vs Q2'23)
-
Share dilution Medical - Pharmaceuticals: +0.0%+9.1% Q2'24: +32.3% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.00× Q2'24: 0.00× (vs Q2'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
est: 3.38B (-100.0%)
|
3.63B
est.
|
3.92B
est.
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBITDA |
-28.17M
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
| EBIT |
-29.19M
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
| Net Income |
-32.34M
est: 618.1K (-5,332.5%)
|
704.1K
est.
|
806.3K
est.
|
-1.06M
-1.06M – -1.06M
-231.5% YoY
|
-1.01M
-1.01M – -1.01M
+5.0% YoY
|
| SGA |
9.91M
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
| EPS |
-30.82
est: 0.59 (-5,332.5%)
|
0.67
est.
|
0.77
est.
|
-1.01
-1.01 – -1.01
-231.5% YoY
|
-0.96
-0.96 – -0.96
+5.0% YoY
|
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ArrowMark Colorado Holdings LLC | 2.59M | 11.40% | 2.59M | — | 2.59M | — | IA | Delaware, United States | 2021-04-12 | ↗ |
| 2 | Barer | 2.39M | 9.17% | 2.39M | — | 2.39M | 11.00 | IN | — | 2023-04-07 | ↗ |
| 3 | Louise F. Brady | 1.56M | 6.88% | 1.56M | — | 16.8K | — | IN | United States America | 2022-02-22 | ↗ |
| 4 | 2. | 1.54M | 6.80% | — | — | 1.54M | — | PN | — | 2022-02-11 | ↗ |
| 5 | Robert E. Long, Jr. | 1.51M | 6.65% | 128.7K | — | 1.38M | — | IN | United States America | 2022-02-18 | ↗ |
| 6 | 6.08% | 1.38M | 6.08% | 1.38M | — | 1.38M | — | OO | — | 2022-02-14 | ↗ |
| 7 | 1,200,000 | 1.20M | 5.30% | 1.20M | — | 1.20M | — | OO | Bermuda | 2021-03-31 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Schwab Fundamental International Small Company Index ETF FNDC | 0.12% | 3.65M | 0.39% |
| 2 | State Street SPDR Portfolio Europe ETF SPEU | 0.02% | 138.9K | 0.07% |
| 3 | WisdomTree International Efficient Core Fund NTSI | 0.02% | 75.1K | 0.26% |
| 4 | Schwab International Equity ETF SCHF | 0.01% | 4.33M | 0.03% |
| 5 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 1.29M | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
1.00
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+1
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-11 | Jones Kristi | Director / Officer | P-Purchase | A | Series A Preferred Stock, par value $0.0001 per share | 1 | 0.01 | 0.01 | 1 | — | ↗ |
| 2024-04-05 | Marchio Albert N II | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-22 | Roemer Alan S. | Director | S-Sale | D | Common Stock | 3,992 | 1.94 | 7.8K | 0 | — | ↗ |
| 2023-11-21 | Roemer Alan S. | Director | S-Sale | D | Common Stock | 3,833 | 2.16 | 8.3K | 3,992 | — | ↗ |
| 2023-08-30 | STOVER TIMOTHY | Officer | — | D | Common Stock | 0 | 0.00 | — | 71,000 | — | ↗ |
| 2023-07-05 | Yao Zhengbin | Director | A-Award | A | Stock Option (right to buy) | 44,983 | 0.29 | 13.0K | 44,983 | — | ↗ |
| 2023-07-05 | Verstandig Grant | Director | A-Award | A | Stock Option (right to buy) | 44,983 | 0.29 | 13.0K | 44,983 | — | ↗ |
| 2023-07-05 | Roemer Alan S. | Director | A-Award | A | Stock Option (right to buy) | 44,983 | 0.29 | 13.0K | 44,983 | — | ↗ |
| 2023-07-05 | Gandhi Leena | Director | A-Award | A | Stock Option (right to buy) | 44,983 | 0.29 | 13.0K | 44,983 | — | ↗ |
| 2023-07-05 | D'Angio Paul | Director | A-Award | A | Stock Option (right to buy) | 44,983 | 0.29 | 13.0K | 44,983 | — | ↗ |
| 2023-07-05 | Bertram Timothy | Director | A-Award | A | Stock Option (right to buy) | 44,983 | 0.29 | 13.0K | 44,983 | — | ↗ |
| 2023-07-05 | BARER SOL J | Director | A-Award | A | Stock Option (right to buy) | 44,983 | 0.29 | 13.0K | 44,983 | — | ↗ |
| 2023-04-04 | Yao Zhengbin | Director | D-Return | D | Stock Option (right to buy) | 61,678 | 1.82 | 112.3K | 0 | — | ↗ |
| 2023-04-04 | Verstandig Grant | Director | D-Return | D | Stock Option (right to buy) | 61,678 | 1.82 | 112.3K | 0 | — | ↗ |
| 2023-04-04 | Trainer John | Officer | D-Return | D | Stock Option (right to buy) | 78,100 | 4.22 | 329.6K | 0 | — | ↗ |
| 2023-04-04 | Roemer Alan S. | Director | D-Return | D | Stock Option (right to buy) | 9,556 | 17.00 | 162.5K | 0 | — | ↗ |
| 2023-04-04 | OELKE MATHIAS | Officer | A-Award | A | Stock Option (right to buy) | 81,100 | 0.41 | 33.3K | 81,100 | — | ↗ |
| 2023-04-04 | Jones Kristi | Director / Officer | D-Return | D | Stock Option (right to buy) | 15,743 | 2.42 | 38.1K | 0 | — | ↗ |
| 2023-04-04 | Gandhi Leena | Director | D-Return | D | Stock Option (right to buy) | 80,947 | 3.07 | 248.5K | 0 | — | ↗ |
| 2023-04-04 | D'Angio Paul | Director | A-Award | A | Stock Option (right to buy) | 23,122 | 1.64 | 37.9K | 23,122 | — | ↗ |
| 2023-04-04 | Bertram Timothy | Director | A-Award | A | Stock Option (right to buy) | 61,678 | 1.64 | 101.2K | 61,678 | — | ↗ |
| 2023-04-04 | BARER SOL J | Director | D-Return | D | Stock Option (right to buy) | 19,113 | 17.00 | 324.9K | 0 | — | ↗ |
| 2023-03-30 | BARER SOL J | Director | P-Purchase | A | Common Stock | 400,000 | 0.41 | 164.1K | 2,217,814 | — | ↗ |
| 2022-11-26 | Jones Kristi | Officer | A-Award | A | Common Stock | 296,700 | 0.00 | — | 369,778 | — | ↗ |
| 2022-11-22 | Trainer John | Officer | A-Award | A | Common Stock | 125,200 | 0.00 | — | 186,969 | — | ↗ |
| 2022-11-22 | OELKE MATHIAS | Officer | A-Award | A | Common Stock | 126,100 | 0.00 | — | 134,023 | — | ↗ |
| 2022-11-17 | BARER SOL J | Director | P-Purchase | A | Common Stock | 75,000 | 0.48 | 35.9K | 1,817,814 | — | ↗ |
| 2022-11-16 | BARER SOL J | Director | P-Purchase | A | Common Stock | 125,000 | 0.48 | 60.3K | 1,742,814 | — | ↗ |
| 2022-06-13 | Yao Zhengbin | Director | A-Award | A | Stock Option (Right to Buy) | 61,678 | 0.00 | — | 61,678 | — | ↗ |
| 2022-06-13 | Verstandig Grant | Director | A-Award | A | Stock Option (Right to Buy) | 61,678 | 0.00 | — | 61,678 | — | ↗ |
| 2022-06-13 | Roemer Alan S. | Director | A-Award | A | Stock Option (Right to Buy) | 61,678 | 0.00 | — | 61,678 | — | ↗ |
| 2022-06-13 | D'Angio Paul | Director | A-Award | A | Stock Option (Right to Buy) | 61,678 | 0.00 | — | 61,678 | — | ↗ |
| 2022-06-13 | Bertram Timothy | Director | A-Award | A | Stock Option (Right to Buy) | 61,678 | 0.00 | — | 61,678 | — | ↗ |
| 2022-06-13 | BARER SOL J | Director | A-Award | A | Stock Option (Right to Buy) | 61,678 | 0.00 | — | 61,678 | — | ↗ |
| 2022-06-03 | Verstandig Grant | Director | P-Purchase | A | Common Stock | 25,000 | 2.14 | 53.5K | 1,078,619 | — | ↗ |
| 2022-05-31 | Verstandig Grant | Director | P-Purchase | A | Common Stock | 40,200 | 2.38 | 95.8K | 990,719 | — | ↗ |
| 2022-05-31 | BARER SOL J | Director | P-Purchase | A | Common Stock | 39,280 | 2.19 | 85.9K | 1,557,094 | — | ↗ |
| 2022-05-05 | Gandhi Leena | Director | A-Award | A | Stock Option (Right to Buy) | 80,947 | 0.00 | — | 80,947 | — | ↗ |
| 2022-04-05 | ZELDIS JEROME B | Officer | A-Award | A | Stock Option (Right to Buy) | 80,100 | 4.22 | 338.0K | 80,100 | — | ↗ |
| 2022-04-05 | Trainer John | Officer | A-Award | A | Stock Option (Right to Buy) | 78,100 | 0.00 | — | 78,100 | — | ↗ |
| 2022-04-05 | OELKE MATHIAS | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-04-05 | Knight Robert Douglas | Officer | A-Award | A | Stock Options (Right to Buy) | 48,000 | 0.00 | — | 48,000 | — | ↗ |
| 2022-04-05 | Jones Kristi | Officer | A-Award | A | Stock Option (Right to Buy) | 456,000 | 0.00 | — | 456,000 | — | ↗ |
| 2022-03-29 | Jones Kristi | Officer | P-Purchase | A | Common Stock | 10,000 | 3.74 | 37.4K | 73,078 | — | ↗ |
| 2022-03-24 | Verstandig Grant | Director | P-Purchase | A | Common Stock | 131,622 | 4.14 | 544.9K | 886,512 | — | ↗ |
| 2022-03-23 | BARER SOL J | Director | P-Purchase | A | Common Stock | 10,000 | 2.67 | 26.7K | 1,517,814 | — | ↗ |
| 2022-03-22 | BARER SOL J | Director | P-Purchase | A | Common Stock | 30,000 | 2.41 | 72.3K | 1,507,814 | — | ↗ |
| 2022-03-21 | BARER SOL J | Director | P-Purchase | A | Common Stock | 30,000 | 2.14 | 64.1K | 1,477,814 | — | ↗ |
| 2022-03-18 | BARER SOL J | Director | P-Purchase | A | Common Stock | 30,000 | 2.11 | 63.2K | 1,447,814 | — | ↗ |
| 2021-12-21 | Roemer Alan S. | Director | M-Exempt | D | Stock Option (right to buy) | 42,389 | 4.31 | 182.7K | 3,856 | — | ↗ |
| 2021-12-21 | BARER SOL J | Director | M-Exempt | A | Common Stock | 50,000 | 5.17 | 258.5K | 1,417,814 | — | ↗ |
| 2021-07-08 | Trainer John | Officer | M-Exempt | D | Stock Option (right to buy) | 3,432 | 5.17 | 17.7K | 102,949 | — | ↗ |
| 2021-06-08 | Trainer John | Officer | M-Exempt | D | Stock Option (right to buy) | 3,432 | 5.17 | 17.7K | 106,381 | — | ↗ |
| 2021-05-08 | Trainer John | Officer | M-Exempt | A | Common Stock | 3,432 | 5.17 | 17.7K | 54,906 | — | ↗ |
| 2021-04-08 | Trainer John | Officer | M-Exempt | D | Stock Option (right to buy) | 3,432 | 5.17 | 17.7K | 113,245 | — | ↗ |
| 2021-03-10 | Trainer John | Officer | M-Exempt | D | Stock Option (right to buy) | 3,432 | 5.17 | 17.7K | 116,677 | — | ↗ |
| 2021-02-17 | ZELDIS JEROME B | Officer | P-Purchase | A | Common Stock | 5,882 | 17.00 | 100.0K | 5,882 | — | ↗ |
| 2021-02-17 | Verstandig Grant | Director | P-Purchase | A | Common Stock | 175,000 | 17.00 | 2.98M | 714,895 | — | ↗ |
| 2021-02-17 | Roemer Alan S. | Director | C-Conversion | D | Series A2 Preferred Stock | 4,110 | 0.00 | — | 0 | — | ↗ |
| 2021-02-17 | Jones Kristi | Officer | P-Purchase | A | Common Stock | 911 | 17.00 | 15.5K | 63,078 | — | ↗ |
| 2021-02-17 | D'Angio Paul | Director | C-Conversion | D | Series A2 Preferred Stock | 4,110 | 0.00 | — | 0 | — | ↗ |
| 2021-02-17 | Carmer Scott | Director / Officer | C-Conversion | D | Series A Preferred Stock | 7,058 | 0.00 | — | 0 | — | ↗ |
| 2021-02-17 | Bertram Timothy | Director | C-Conversion | A | Common Stock | 16,440 | 0.00 | — | 78,199 | — | ↗ |
| 2021-02-17 | BARER SOL J | Director | C-Conversion | A | Common Stock | 337,365 | 125,000,000.00 | 42.17T | 1,478,013 | — | ↗ |
| 2021-02-11 | ZELDIS JEROME B | Officer | A-Award | A | Stock Option (right to buy) | 351,016 | 17.00 | 5.97M | 351,016 | — | ↗ |
| 2021-02-11 | Yao Zhengbin | Director | A-Award | A | Stock Option (right to buy) | 9,556 | 17.00 | 162.5K | 32,678 | — | ↗ |
| 2021-02-11 | Verstandig Grant | Director | — | D | Convertible Promissory Note | 538,771 | 0.00 | — | 0 | — | ↗ |
| 2021-02-11 | Trainer John | Officer | A-Award | A | Stock Option (right to buy) | 28,987 | 17.00 | 492.8K | 149,096 | — | ↗ |
| 2021-02-11 | Roemer Alan S. | Director | A-Award | A | Stock Option (right to buy) | 9,556 | 17.00 | 162.5K | 104,191 | — | ↗ |
| 2021-02-11 | Knight Robert Douglas | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-11 | Jones Kristi | Officer | — | D | Stock Option (right to buy) | 88,156 | 2.58 | 227.4K | 0 | — | ↗ |
| 2021-02-11 | D'Angio Paul | Director | — | D | Stock Option (right to buy) | 12,634 | 2.42 | 30.6K | 0 | — | ↗ |
| 2021-02-11 | Carmer Scott | Director / Officer | — | D | Stock Option (right to buy) | 59,640 | 4.31 | 257.0K | 0 | — | ↗ |
| 2021-02-11 | Bertram Timothy | Director | — | D | Common Stock | 0 | 0.00 | — | 6,450 | — | ↗ |
| 2021-02-11 | BARER SOL J | Director | — | I | Series A3 Preferred Stock | 82,204 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.39M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Kristi Jones President and Chief Executive Officer | 511.8K | 148.8K | — | 1.47M | — | 19.8K | 2.15M | 68.39% | ↗ |
| 2 | 2022 | Jerome Zeldis EVP, Head of Research & Development | 398.9K | 173.3K | — | 234.6K | — | 46.0K | 852.8K | 27.51% | ↗ |
| 3 | 2022 | John Trainer Chief Financial Officer | 384.3K | 146.0K | — | 285.1K | — | 15.8K | 831.2K | 34.30% | ↗ |
| 4 | 2022 | Mathias Oelke Chief Science Officer | 352.7K | 115.5K | — | 232.5K | — | 35.6K | 736.3K | 31.57% | ↗ |
| 5 | 2022 | Scott Carmer President and Chief Executive Officer | 219.0K | — | — | — | — | 2.4K | 221.5K | 0.00% | ↗ |
| 6 | 2021 | Jerome Zeldis EVP, Head of Research & Development | 396.0K | — | — | 3.94M | — | 9.8K | 4.34M | 90.65% | ↗ |
| 7 | 2021 | Scott Carmer President and Chief Executive Officer | 509.2K | 195.7K | — | 3.59M | — | 9.0K | 4.30M | 83.40% | ↗ |
| 8 | 2021 | Kristi Jones President and Chief Executive Officer | 362.8K | 142.9K | — | 984.5K | — | 15.2K | 1.51M | 65.40% | ↗ |
| 9 | 2021 | Kristi Jones Chief Operating Officer | 362.8K | 142.9K | — | 984.5K | — | 15.2K | 1.51M | 65.40% | ↗ |
| 10 | 2021 | John Trainer Chief Financial Officer | 362.0K | 138.0K | — | 338.9K | — | 14.7K | 853.6K | 39.70% | ↗ |
| 11 | 2020 | John Trainer Chief Financial Officer | 329.1K | — | — | 669.0K | — | 8.8K | 1.01M | 66.45% | ↗ |
| 12 | 2020 | Scott Carmer President and Chief Executive Officer | 388.3K | 122.4K | — | — | — | 7.7K | 518.4K | 0.00% | ↗ |
| 13 | 2020 | Kristi Jones Chief Operating Officer | 308.2K | 77.7K | — | — | — | 11.6K | 397.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2024-08-02 | DEFA14A | ↗ |
| 2024-07-19 | DEFA14A | ↗ |
| 2024-07-11 | DEFA14A | ↗ |
| 2024-06-21 | DEF 14A | ↗ |
| 2024-06-11 | PRE 14A | ↗ |
| 2024-02-06 | DEFA14A | ↗ |
| 2024-01-18 | DEFA14A | ↗ |
| 2023-11-20 | DEF 14A | ↗ |
| 2023-11-09 | PRE 14A | ↗ |
| 2023-09-25 | DEF 14A | ↗ |
| 2023-09-13 | PRE 14A | ↗ |
| 2023-04-04 | DEFA14A | ↗ |
| 2023-04-04 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Trainer | Consultant | 1M | male |
| Robert Douglas Knight | Chief Medical Officer | 454.8K | — |
| Daniel Bednarik | Senior Vice President of Molecular Engineering & Protein Design | — | — |
| Jack A. Ragheb | Senior Vice President of Translational Science | — | — |
| Chad Rubin | Senior Vice President of Corporate Affairs | — | male |
| Karen Haslbeck | Head of Human Resources | — | female |
| Matthew Schiller | Head of Business Development | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NEXI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
